Log In
Print
BCIQ
Print
Print this Print this
 

ALM201

  Manage Alerts
Collapse Summary General Information
Company Almac Group Ltd.
DescriptionTubulin disrupting agent with anti-angiogenic properties
Molecular Target CD44
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner Shin Poong Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$20.2M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today